Hengrui Medicine Releases 2020 Annual Report: Large R&D Investment; Revenue of Anti-tumor Products Increased by More than 44%-Stock-Financial


Full Data

?
UNLOCK DATA

Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets


Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!


Already have an account?
Login